Report overview
The global Ofatumumab market was valued at million in 2024 and is projected to reach US$ million by 2032, at a CAGR of %during the forecast period.
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the EU and other regions.
The U.S. market size is estimated at $ million in 2024, while China is to reach $ million.
Patent segment will reach $ million by 2032, with a % CAGR in next six years.
The global key manufacturers of Ofatumumab include BOC Sciences, GlaxoSmithKline(GSK), Lonza Group, Novartis International, TargetMol Chemicals, Hubei Kele Fine Chemical, Jiangxi Ruiweier Biotechnology, Nantong Feiyu Biological Technology, Shanghai Biochempartner, Shanghai Macklin Biochemical, etc. In 2024, the global top five players had a share approximately % in terms of revenue.
We have surveyed the Ofatumumab manufacturers, suppliers, distributors, and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for Ofatumumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ofatumumab. This report contains market size and forecasts of Ofatumumab in global, including the following market information:
Global Ofatumumab market revenue, 2020-2025, 2026-2032, ($ millions)
Global Ofatumumab market sales, 2020-2025, 2026-2032, (Kg)
Global top five Ofatumumab companies in 2024 (%)
Total Market by Segment:
Global Ofatumumab market, by Type, 2020-2025, 2026-2032 ($ millions) & (Kg)
Global Ofatumumab market segment percentages, by Type, 2024 (%)
Patent
Generic
Global Ofatumumab market, by Application, 2020-2025, 2026-2032 ($ Millions) & (Kg)
Global Ofatumumab market segment percentages, by Application, 2024 (%)
Chemical
Pharmaceutical
Global Ofatumumab market, by region and country, 2020-2025, 2026-2032 ($ millions) & (Kg)
Global Ofatumumab market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ofatumumab revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies Ofatumumab revenues share in global market, 2024 (%)
Key companies Ofatumumab sales in global market, 2020-2025 (estimated), (Kg)
Key companies Ofatumumab sales share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
BOC Sciences
GlaxoSmithKline(GSK)
Lonza Group
Novartis International
TargetMol Chemicals
Hubei Kele Fine Chemical
Jiangxi Ruiweier Biotechnology
Nantong Feiyu Biological Technology
Shanghai Biochempartner
Shanghai Macklin Biochemical
Shanghai Yifei Biotechnology
Tianmen Hengchang Chemical
Wuhan Topule Biopharmaceutical
Wuhan Wogeda Biotechnology
Wuhan Yingnuo Pharmaceutical Technology
Outline of Major Chapters:
Chapter 1: Introduces the definition of Ofatumumab, market overview.
Chapter 2: Global Ofatumumab market size in revenue and volume.
Chapter 3: Detailed analysis of Ofatumumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Ofatumumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Ofatumumab capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
